BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Lenvatinib: trial readouts and FDA decisions
5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, 3D Medicines (Sichuan) Co., Ltd., Merck Sharp & Dohme LLC, Akeso, Lion TCR Pte. Ltd., Mirror Biologics, Inc., AbbVie, Hoffmann-La Roche. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | Akeso | NCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | HCC; Hepatocellular Carcinoma | not yet recruiting | 120 |
| 2026-11-30 est. | P2 | AstraZeneca AZN | NCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 114 |
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12 est. | P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05112991 Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | Advanced Endometrial Cancer | recruiting | 108 |
| 2026-12 est. | P2 | Lion TCR Pte. Ltd. | NCT05195294 Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma | not yet recruiting | 55 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-01 est. | P2/P3 | Mirror Biologics, Inc. | NCT05033522 Immunotherapy for Advanced Liver Cancer | Hepatocellular Carcinoma | suspended | 150 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab | Hepatocellular Carcinoma | active not recruiting | 130 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10-14 est. | P3 | Hoffmann-La Roche | NCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and B | Unresectable Hepatocellular Carcinoma | active not recruiting | 557 |
| 2026-08-10 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Carcinoma, Renal Cell | completed | 393 |
| 2026-07-23 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | Carcinoma, Renal Cell | completed | 263 |
| 2026-07-09 | P3 | Bristol-Myers Squibb BMY | NCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 732 |
| 2026-05-23 | P3 | BeOne Medicines ONC | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | Advanced Malignancies | completed | 404 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.